CARDIOVASCULAR
hamburger

HeartMate 3 LVAD Therapy from Abbott

Abbott has been a leader in heart pump technology for more than 20 years. You should feel confident with a HeartMate 3™ LVAD to treat your heart failure. Here's why:

Abbott’s heart pumps have set the standard in LVAD therapy. The HeartMate 3 LVAD is the most advanced LVAD yet. It is the only LVAD that uses a patented technology which helps protect the blood as it flows through the pump.

In the largest LVAD clinical trial* ever conducted, HeartMate 3 LVAD had outstanding clinical results and a high survival rate similar to heart transplant 2 years after surgery.1,2+
 

HeartMate 3 LVAD Therapy Helps People with Advanced Heart Failure:1

  • Reverse the symptoms of heart failure
  • Live longer
  • Live active, full lives with a better quality of life

Understanding HeartMate 3 LVAD Therapy

Watch this video to learn about HeartMate 3 LVAD therapy and how it can help people with advanced heart failure.


Associated risks of LVAD therapy can include bleeding, stroke, thrombosis and other possible adverse events.


“When my cardiologist told me I qualified for the HeartMate 3, I asked if they could put it in that afternoon. Ever since I've had my HeartMate 3, every day has been just amazing.”

— Dave V., HeartMate 3 LVAD Recipient.

This testimonial relates an account of an individual’s response to the treatment. This patient’s account is genuine, typical and documented. However, it does not provide any indication, guide, warranty or guarantee as to the response other persons may have to the treatment. Responses to the treatment discussed can and do vary and are specific to the individual patient.


Live a More Active Life With an LVAD

See what real people have to say about life after receiving their HeartMate 3 LVAD.

HeartMate 3 Patient Stories

* A clinical trial is a type of research that studies a test or treatment given to people.
+ 82% 2-year survival for adult heart transplant patients between 2009 and 2015.

Results based on published data from multicenter experience and separate studies, which may involve different patient populations and other variables. Not a head-to-head comparison. Data presented for informational purposes only.


References

  1. Mehra MR, Uriel N, Naka Y, et al. A Fully Magnetically Levitated Ventricular Assist Device-Final Report. N Engl J Med. 2019;380:1618-1627.
  2. Khush KK, Cherikh WS, Chambers DC, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-fifth Adult Heart Transplant Report-2018; Focus Theme: Multiorgan Transplantation. J Heart Lung Transplant. 2018;37:1155-1168.
INDICATIONS, SAFETY & WARNINGS

MAT-2108557 v1.0

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

False
accessibility
© 2019 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.